Study to evaluate the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the pharmacokinetics (PK)/bioavailability of palovarotene, and evaluate the effect of palovarotene on the PK of the CYP3A4 substrate midazolam.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
48
oral capsules
oral syrup
Cambridge Ipsen US
Cambridge, Massachusetts, United States
Maximum (peak) observed plasma drug concentration
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13.
Time to reach maximum (peak) (t max) observed plasma concentration following drug administration
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Area under the plasma concentration time (AUC 0-last) curve from time zero to the last quantifiable time point, calculated by linear-log trapezoidal summation
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Area under the plasma concentration time curve from time zero to infinity (AUC 0-infinity)
calculated by linear-log trapezoidal summation and extrapolated to infinity by addition of the last quantifiable plasma concentration divided by the elimination rate constant
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Apparent terminal disposition rate constant/terminal rate constant yz
determined by linear regression of the terminal points of the log-linear plasma concentration-time curve
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Apparent terminal elimination half-life (t1/2)
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Apparent volume of distribution after oral administration (Vd/F)
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Apparent total clearance of the drug from plasma after oral administration (cLF)
Time frame: Days 1, 2, 3, 6, 7, 8, 11, 12, 13
Area under the plasma concentration time curve from time zero to 24 hours only for DDI cohort
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Days 1, 2, 15, 16
The last concentration before the next study drug administration at steady state for DDI cohort
Time frame: Days 1, 2, 15, 16
Maximum (peak) observed plasma drug concentration at steady state for DDI cohort
Time frame: Days 1, 2, 15, 16
Time to reach maximum (peak) observed plasma concentration following drug administration at steady state for DDI cohort
Time frame: Days 1, 2, 15, 16
Minimum observed plasma concentration at steady state, taken as the lowest plasma concentration during dosing interval for DDI cohort
Time frame: Days 1, 2, 15, 16
Accumulation ratio for DDI cohort
Time frame: Days 1, 2, 15, 16
Occurrence of Adverse Events (AEs)
Time frame: from baseline until the end of study (16 days)